BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
CRBP upcoming catalysts
Corbus Pharmaceuticals Inc.: 1 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 0 FDA event(s). Subscribe to CRBP (.ics).
Drugs: CRB-701, Anti-PD-1, Anti-PD-1 monoclonal antibody
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01-16 est. | P1/P2 | Corbus Pharmaceuticals Inc. CRBP | NCT06265727 A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Solid Tumor, Adult | recruiting | 348 |
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-01-30 | P1/P2 | Corbus Pharmaceuticals Inc. CRBP | NCT06603844 First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Solid Tumor | completed | 51 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.